Biogen Inc. and Stoke Therapeutics announced publication in The New England Journal of Medicine of data from two completed Phase 1/2a studies and ongoing open-label extension studies of the investigational RNA medicine zorevunersen in children and adolescents with Dravet syndrome. The publication reports reductions in major motor seizure frequency and measures of neurodevelopment and quality of life over the Phase 1/2a period and up to three additional years in extension follow-up, with safety findings including cerebrospinal fluid protein elevations. The companies said the data support the ongoing global Phase 3 EMPEROR study, with results expected in mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603041705OMX_____CNEWS_EN_GNW9666071_en) on March 04, 2026, and is solely responsible for the information contained therein.